Heipram

Heipram is a prescription medication that contains the active ingredient escitalopram oxalate, a selective serotonin reuptake inhibitor (SSRI). It is marketed in the European Union and is supplied as an oral dosage form, though specific strength information is not disclosed. Heipram is used under medical supervision to manage certain mood and anxiety disorders, and it requires a prescription from a qualified health professional.

Heipram is indicated for the treatment of several psychiatric conditions that involve dysregulated serotonin pathways. It is commonly prescribed as part of a broader therapeutic plan that may include counseling or other pharmacologic agents.

- Major depressive disorder (MDD) - Generalized anxiety disorder (GAD) - Social anxiety disorder (SAD) - Panic disorder with or without agoraphobia - Adjunctive therapy for other mood disorders as determined by a clinician

Side effects of Heipram can vary in frequency and severity. Patients should be aware of both common reactions and those that may require immediate medical attention.

Common: - Nausea or upset stomach - Headache - Insomnia or somnolence - Dry mouth - Increased sweating - Dizziness

Serious: - Suicidal thoughts or behavior - Serotonin syndrome (e.g., agitation, fever, rapid heart rate) - Severe allergic reaction (e.g., rash, swelling, difficulty breathing) - Abnormal heart rhythm (QT prolongation)

Before starting Heipram, certain health considerations should be reviewed with a health care provider to ensure safe use.

- History of bipolar disorder or mania, as SSRIs may trigger mood switching - Existing cardiac conditions, especially those affecting QT interval - Liver or kidney impairment, which may affect drug clearance - Pregnancy or breastfeeding status, due to limited safety data - Concomitant use of other serotonergic agents, increasing risk of serotonin syndrome - Monitoring for worsening depression or emergence of suicidal thoughts, particularly in early treatment phases

Heipram can interact with other medications, altering its effectiveness or increasing the risk of adverse effects. Interactions are grouped by the level of clinical concern.

Avoid: - Monoamine oxidase inhibitors (MAOIs) and within 14 days of stopping an MAOI - Other serotonergic drugs (e.g., triptans, tramadol, linezolid) - Certain antiarrhythmic agents that prolong QT interval (e.g., sotalol, amiodarone)

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and anticoagulants (increased bleeding risk) - CYP2C19 or CYP3A4 inhibitors (e.g., fluconazole, erythromycin) that may raise escitalopram levels - Alcohol, which can enhance central nervous system depression